Announced details
enzomenib ORR: 54% in the 200mg BID group and 57% in the 300mg BID group. CR+CRh rate: 35% in the 200mg BID group and 43% in the 300mg BID group.
Sumitomo Pharma America, Inc., Sumitomo Pharma's US subsidiary, will present clinical data at the meeting.
A professional society in the field of hematology. Its 2026 Annual Meeting is scheduled to be held in New Orleans, US, from 12 December 2026 to 15 December 2026.
FDA Breakthrough Therapy designation, FDA Fast Track designation, FDA Orphan Drug designation, Ministry of Health, Labour and Welfare orphan drug designation, EMA Orphan designation
U.S. Food and Drug Administration (FDA)
Ministry of Health, Labour and Welfare
European Medicines Agency (EMA)
New Orleans Ernest N. Morial Convention Center (New Orleans, US)
No information was provided on the impact on business performance.
The company does not address Contract Value / Offering price.
Data to be presented at the 2026 ASH Annual Meeting
| Item | Details |
|---|---|
| Names of Products / Services Covered | enzomenib（DSP-5336）, nuvisertib（TP-3654） |
| Counterparty | American Society of Hematology (ASH) |
| Counterparty overview | A professional society in the field of hematology. Its 2026 Annual Meeting is scheduled to be held in New Orleans, US, from 12 December 2026 to 15 December 2026. |
| Relationship with the Company | Sumitomo Pharma America, Inc., Sumitomo Pharma's US subsidiary, will present clinical data at the meeting. |
| Launch date | 12 December 2026 to 15 December 2026 (scheduled meeting dates) |
| Applicable area | Relapsed or refractory acute leukemia with a KMT2A gene rearrangement, Relapsed or refractory acute leukemia with an NPM1 gene mutation, Myelofibrosis in patients previously treated with a JAK inhibitor, Myelofibrosis with anemia |
| Award/certification name | FDA Breakthrough Therapy designation, FDA Fast Track designation, FDA Orphan Drug designation, Ministry of Health, Labour and Welfare orphan drug designation, EMA Orphan designation |
| Awarding / certifying body | U.S. Food and Drug Administration (FDA), Ministry of Health, Labour and Welfare, European Medicines Agency (EMA) |
| Location | New Orleans Ernest N. Morial Convention Center (New Orleans, US) |
| Quantitative Effects | enzomenib ORR: 54% in the 200mg BID group and 57% in the 300mg BID group. CR+CRh rate: 35% in the 200mg BID group and 43% in the 300mg BID group. |
| Impact on Business Performance | No information was provided on the impact on business performance. |
| Source | Data to be presented at the 2026 ASH Annual Meeting |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To help improve treatment outcomes for patients with acute leukemia or myelofibrosis, for whom treatment options are limited.